Xeris Biopharma (NASDAQ:XERS) Director John Johnson Sells 107,500 Shares

Key Points

• John Johnson, a director at Xeris Biopharma, sold 107,500 shares of the company's stock for approximately $786,900, reducing his holdings by 11.42%.
• Xeris Biopharma reported a net revenue of $67.71 million for the last quarter, exceeding analyst expectations and achieving earnings per share of ($0.01), which was better than the forecast of ($0.03).
• Several analysts have recently upgraded their ratings on Xeris Biopharma's stock, with the company receiving a consensus rating of "Buy" and a price target averaging around $6.58.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director John Johnson sold 107,500 shares of Xeris Biopharma stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total value of $786,900.00. Following the transaction, the director owned 833,483 shares in the company, valued at $6,101,095.56. This represents a 11.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Xeris Biopharma Stock Performance

NASDAQ:XERS traded up $0.21 during trading hours on Wednesday, hitting $7.57. 1,617,397 shares of the company's stock traded hands, compared to its average volume of 3,286,943. The stock's fifty day moving average price is $5.40 and its two-hundred day moving average price is $4.79. The firm has a market cap of $1.22 billion, a P/E ratio of -36.05 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a twelve month low of $2.48 and a twelve month high of $7.79.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on XERS shares. Oppenheimer upped their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, HC Wainwright started coverage on Xeris Biopharma in a research note on Tuesday, August 12th. They set a "buy" rating and a $10.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $6.58.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Xeris Biopharma by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock valued at $44,522,000 after purchasing an additional 210,581 shares during the period. Geode Capital Management LLC increased its position in Xeris Biopharma by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company's stock worth $17,052,000 after buying an additional 244,862 shares during the period. Qube Research & Technologies Ltd lifted its holdings in shares of Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company's stock worth $14,429,000 after buying an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock valued at $12,726,000 after acquiring an additional 369,420 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.